Aptamer Therapeutics in Cancer: Current and Future.

1. Advantages of Aptamers

Molecularly targeted therapy is broadly adopted for treatment of many cancer types as an opportunity to inhibit oncogene function. Currently, chimeric monoclonal antibodies as well as small molecule inhibitors are the clinical mainstays in this class of agents. Aptamers, or so called “chemical antibodies,” represent a new class of molecular targeting agents as a result of their unique properties, such as ease of synthesis and modification as well as high affinity binding and excellent safety profiles.

The structural base of aptamers is composed of short DNA or RNA oligonucleotides ranging around 15–100 nt that form complex tertiary or quadruplex structures through hybridization of complementary sequences [ 1 ]. Large surface areas, despite their small molecular weight (5–30 kDa), permit high-affinity binding to their molecular targets [ 1 ]. The dissociation constant (Kd) of an aptamer’s target is generally in the range of several micro- to pico-molars [ 2 , 3 ], which is comparable to antibody therapeutics. In contrast, small molecule inhibitors (Tyrosine kinase inhibitors: TKI) function as ATP mimetics, thus their sizes are small enough to occupy the ATP binding pocket of the intracellular domain of a receptor tyrosine kinase and are responsible for their relatively large Kd [ 4 ]. For example, gefitinib (Iressa ® , AstraZeneca, Chesire, UK), the TKI for EGFR, binds with wild-type EGFR kinase at a Kd of 53.5 nM [ 5 ], while the Kd of cetuximab (Erbitux ® , ImClone, Branchburg, NJ, USA), an inhibitory anti-EGFR antibody, is far smaller, 2.3 nM [ 6 ]. A nuclease resistant 2′-fluoropyrimidines-containing RNA aptamer, named CL4 and E07, a 2′-fluoropyrimidine modified anti-EGFR aptamer display Kd comparable to antibody, at 10 nM [ 7 ] and 2.4 nM, respectively [ 8 ].

Aptamer backbones are synthesized automatically through cell-free assembly that enables cost effective and rapid bulk production with minimal batch-to-batch variation. Additionally, aptamers’ structural stability affords them an extensive storage period as well as the ability to withstand a broad range of temperatures. They are stable at ambient temperature and heat resistant, thus their functional tertiary structure is readily regenerated following heat denaturation. Another significant advantage of aptamers is their capacity for site-specific chemical modifications. Oligonucleotide sugar, base, and phosphate backbone modifications as well as a variety of unnatural oligonucleotides make up the wide repertoire of chemical alterations available to aptamers. Methods for base substitutions including 2′-fluoro- [ 9 , 10 , 11 ], 2′-amino-, 2′-azido-, 2′-hydroxymethyl-, and 2′-methoxypyrimidines and 2′-methoxypurines have been established [ 12 , 13 , 14 , 15 ]. Phosphorothioate and phosphorodithioate substitutions are another option for the backbone modification [ 16 ]. Such chemical modifications of the DNA backbone provide resistance against nucleases, as was first shown by Eckstein’s group [ 17 ], and often increase binding affinity [ 16 ]. The introduction of functional groups in the aptamer backbone permits conjugation to other drugs, siRNA [ 18 , 19 ], and nanoparticles [ 20 , 21 , 22 ], further broadening their application as multivalent therapeutics [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ].

2. Challenges and Possible Solutions in Aptamer Therapeutics

2.1. Aptamer Stability

For treatment of malignancies, it is ideal that drugs remain in circulation for extended periods to increase chance of cancer cell exposure to drugs. Thus, the pharmacokinetic profile and bioavailability of injectable drugs are critical determinants of therapeutic efficacy. In this respect, humanized antibodies are superior to other drug entities, displaying circulation half-lives from days to weeks [ 31 ]. Unmodified nucleotides, however, may have a serum half-life as short as few minutes [ 32 ]. This unfavorable pharmaceutical property represents one the critical challenges facing realistic clinical application of aptamers. Two contributing factors for this are their susceptibility to nuclease degradation and renal excretion. Nucleases are abundantly present in biological fluids, and both exo - and endo -nucleases cleave phosphodiester bonds of single and double stranded oligonucleotides [ 1 ]. The average time of oligonucleotide decay in the blood depends on their structure, and ranges from several minutes to several tens of minutes [ 1 ]. Since such a short half-life is undesirable for therapeutic applications, oligonucleotides are typically chemically modified to improve the serum stability [ 3 ]. For instance, simple alteration of the 2′-OH group on ribose to 2′-amino (NH 2 ) or 2′-fluoro-modified sugars on pyrimidines can successfully confer resistance to breakdown in the serum for over 2 days [ 33 ] and remains present in the eyes after 28 days [ 34 ]. Thus, current clinically used aptamers [ 35 ] employ chemical modifications such as replacing 2’-OH with fluoro [ 8 , 36 ], NH 2 [ 13 , 37 ], or O-methyl [ 38 , 39 ] groups at the 2′ position or capping the 3′ end with inverted thymidine to overcome nuclease degradation. Anti-human TNFα RNA aptamer which exhibits increased stability with the 2′-NH 2 and 2′-fluoro modifications is one example using these methods. While degradation half-life of the unmodified TNFα RNA aptamer in the serum was several minutes, 2′-NH 2 and 2′-fluoro modifications extended to 8 h [ 13 ]. Another study indicated that a RNA aptamer with 2-O-methyl-modification of all nucleotides in the backbone was stable in RNase rich mycoplasma-contaminated media for more than 4 h, whereas the stability of the modification on pyrimidines only was less than 30 min [ 39 ]. Thiophosphate-substituted aptamers, called thioaptamers, enhance stability by replacing one (monothioaptamer) or both (dithioaptamer) of the non-bridging phosphoryl oxygens in the oligonucleotide phosphate backbone with sulfur [ 40 ]. In addition to stabilization, thioation enhanced binding affinity as well, owing to decreased negative charge on DNA backbone [ 40 ]. Dithioaptamer developed by Gorenstein’s group [ 16 ] showed an increased binding affinity up to 28–600 fold compared to monothioaptamer [ 41 ]. “Mirror aptamers” (Spiegelmers) with oligonucleotide backbones composed of l -ribose (RNA Spiegelmers) or l -deoxy-ribose (DNA Spiegelmers) also lead to nuclease resistance. Spiegelmers, l -form aptamers that are natural d -form chiral inversions are not recognized by nucleases, and therefore display increased stability compared to their natural d -nucleic acid counterparts [ 42 ]. Pfander et al. developed a novel initiator nucleotide that resulted in an aldehyde modification of the 5′-end of RNA, which can be further modified with amino- or hydrazine-functionalized groups [ 43 ]. A38, an unmodified DNA aptamer for Vaccinia virus, also exhibits high stability [ 44 ] that may result from three-dimensional structures protecting the 3′- and 5′-termini of the aptamer from exonucleases. Examples of unmodified aptamer structures that confer high nuclease degradation resistance include closed ring structures at both terminal ligations or ligation of several different aptamers, forming closed structures with multiple specificities [ 45 , 46 ]. The degradation half-life of unligated “open” TS-1 aptamer (DNA aptamer bearing L-selectin-hairpin head) was 4.8 and 16 h in pooled human serum and plasma respectively, while the ligated “closed” TS-1 aptamer significantly increased the stability against nucleases to 9.5 and 50 h, respectively [ 45 ].

2.2. Renal Excretion

The primary excretion routes of injectable drugs are through the kidneys and liver. With aptamer sizes ranging from 5 to 30 kDa, the average diameter of aptamers is less than 5 nm [ 47 ], so most aptamers are smaller than the renal filtration threshold of glomeruli (i.e., 50 kDa) and are excreted from the kidney, regardless of their nuclease resistance. One common solution to overcome rapid renal excretion is augmentation of the aptamer’s overall size through conjugation with high molecular weight moieties such as polyethylene glycol (PEG) [ 48 ], cholesterol [ 49 , 50 ], protein [ 51 , 52 ], multimerization [ 53 , 54 , 55 ], or nanomaterials [ 56 , 57 , 58 ]. PEG is a US Food and Drug Administration (FDA) approved [ 59 ] hydrophilic biocompatible material that has been adopted in 12 biopharmaceuticals currently marketed for human use [ 60 ]. PEG is commercially available in a variety of sizes (0.3 to 10,000 kDa), with different terminal functional groups for chemical conjugation. For aptamer application, PEG is widely used for enlargement of the size [ 61 ] as well as addition of stealth effect to increase their retention in circulation. Macugen ® (OSI Pharmaceuticals, Melville, USA) is composed of a RNA aptamer backbone conjugated with 40 kDa PEG, and exhibits prolonged plasma half-life of 9.3 h via intravenous injection, 12 h via subcutaneous injection [ 33 ], and 94 h via vitreous humor [ 34 ]. Similarly, conjugation of 40 kDa PEG to a 2′-fluoro-/2′- O -methyl modified aptamer resulted in an increase of the circulation half-life to 23 h in a mouse model [ 48 ]. However, high molecular weight PEG conjugation may cause a functional hindrance of the aptamer binding to its target [ 62 ]. Thus the size of PEG as well as type and length of linkage of PEG to aptamer should be determined in a case-by-case fashion. Cholesterol and sugar-based polymers are alternative options for this purpose. Cholesterol conjugation to factor IXa specific aptamer prolonged its half-life significantly in pigs, increasing from only 5 to 10 min for the unmodified aptamer up to 1 to 1.5 h for the conjugated ones [ 49 ].

2.3. Safety of Aptamers

Several factors including aptamer sequence, dose (single and cumulative), route, and chemical modifications may contribute to adverse effects [ 63 ]. Intravenously administered aptamers are generally well tolerated; however, a few adverse effects related to dose and sequence have been reported [ 64 , 65 ]. Studies have shown that intravenously administered aptamers diffuse rapidly into the tissues of various organs, accumulating primarily in the liver, kidney, and spleen [ 66 ]. Accumulation of oligonucleotides in various tissues has been qualitatively measured by immunohistochemistry, in situ hybridization, or histopathology [ 67 , 68 ]. A study by Geary et al. found the accumulation of human TNFα antisense phosphorothioate aptamer in the kidneys, livers, lymph nodes, and spleens of mice and primates [ 66 ]. Administration of aptamers via peritoneum (100 mg/kg) and vein (50 mg/kg) caused reversible kidney and liver abnormalities in mice with a recovery period of 4 to 13 weeks [ 69 , 70 , 71 ]. Infiltration of mononuclear cells and hypertrophy of Kupffer cells in the liver as well as basophilic granules in the cytoplasm of tubular epithelial cells in the kidneys were reported [ 71 , 72 , 73 ].

Liver metabolism of oligonucleotides may result in hepatotoxicity. Kang et al. reported no definitive evidence of sinusoidal dilation, Kupffer cell hypertrophy, or perivascular inflammatory infiltrate in the liver after intravenous bolus injection of E-selectin antagonistic thioaptamer (ESTA) at a dose up to 500 μg twice weekly for 4 weeks, compared to saline injected control mice [ 74 ]. A slight elevation of transaminases aspartate aminotransferase (AST) and alanine aminotransferase (ALT) was noted, although the levels were still within normal range. Similarly, Phase I and II clinical trials of mipomersen, a phosphorothioate antisense oligonucleotide for apolipoprotein B synthesis inhibitor, showed transient dose-dependent elevation of AST and ALT over 5-week treatment (30–400 mg/week) [ 75 , 76 ]. In a randomized, placebo-controlled, dose-escalation Phase II study of mipomersen for 5–13-week treatment, an increase of ALT was noted among 17% of patients (10 of 59 cases), to a level more than three times the upper limit of the normal range [ 76 ]. In phase III trials, elevation of ALT with grade 2–4 (3-fold greater than upper limit of normal) was observed in 17.9% of patients (28 out of 156) who received mipomersen for 26 weeks treatment compared to the placebo arm [ 77 , 78 , 79 , 80 ].

Unintended anticoagulation effects have also been reported in ISIS 2302, a 20-mer antisense phosphorothioate oligonucleotide targeting human intercellular adhesion molecule-1 (ICAM-1) mRNA [ 81 ]. Prolongation of prothrombin and thrombin coagulation times was observed in in vitro assays in human plasma at concentrations of ISIS 2302 >100 μg/mL. Additionally, in a placebo-controlled trial of ISIS 2302 for the treatment of Crohn’s disease, intravenous infusion of ISIS 2302 (2 mg/kg) over 2 h caused a transient (2–4 h after dosing) increase in the activated partial thromboplastin time by approximately 10 seconds, compared to saline placebo infusion [ 82 ]. However, no increase in bleeding time was noted.

Complement activation through the interaction of oligonucleotides has been reported. Repeated bolus intravenous injections of PEGylated E-selectin thioaptamer at a dose of 128 μg resulted in a 2-fold increase of plasma C3a level in mice compared with saline injected mice, though the level of increase was far less than the level of symptomatic hypersensitive reaction [ 62 ]. Henry et al. reported that a single dose of intravenous 10-min infusion of 20 mg/kg ISIS 2302 caused an increase of complement split products Bb and C5a (100- and 7-fold, respectively), accompanied by changes in blood pressure, neutrophil count, and serum cytokine levels (i.e., increases in IL-6, MCP-1, and IL-12) in primates. These changes were observed at or near the end of infusion, which led to death in one of the three primates approximately 4 h after infusion. This study demonstrated that complement pathway activation in primates was related to rapid infusion of phosphorothioate oligonucleotides [ 83 ]. Co-administration of CAB-2m, a complement activation inhibitor, alleviated complement pathway activation along with other clinical symptoms [ 84 ].

Since aptamers are synthetic nucleic acids, it is possible for them to be recognized by the innate immune system via germline-encoded-pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) and retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) [ 85 ]. Activation of Toll-like Receptor 3 (TLR 3), TLR 7, TLR 8 or TLR 9 induces immunity upon recognizing pathogen-derived nucleic acids [ 86 ]. Accordingly, TLR9 responds to unmethylated CpG motifs in DNA, TLR3 to double-stranded RNA, and TLR7 and TLR8 to single-stranded RNA [ 87 ]. Studies showed that the endocytosis of unmethylated CpG motif of DNA into dendritic cells or B cells expressing TLR9 triggers both innate and adaptive immune responses [ 88 , 89 ] and induces inflamatory cascades [ 88 , 89 , 90 ]. The CpG motif consists of an unmethylated CpG dinucleotide flanked by particular base contexts, such as two 5′-purines and two 3′-pyrimidines [ 91 ]. For example, the CpG motif with the “TCAACGTT” sequence was shown to induce B cell activation, whereas a similar sequence, “TCATCGAT”, had no effect on B cell activation. Interestingly, immunogenicity was either absent or limited even if pegaptanib doses 1000-fold higher than clinically required were intravenously administered to primates [ 92 , 93 ]. While development of antibodies against synthetic oligonucleotides is uncommon [ 93 ], it is noteworthy that antibodies to PEG may cause an adverse effect due to frequent exposure to PEGylated products [ 94 ]. In a phase II trial of pegloticase with 10 kDa PEG for refractory gout at a dose of 8 mg intravenous infusion every 3 weeks, 13 of 30 (43%) patients with pre-existing antibody against PEG experienced more frequent infusion reactions (eight of 13 patients, 62%) than patients without (five of 17 patients, 29%) [ 95 ].

3. Aptamers as Therapeutics under Investigation in Oncology

The main strategy of aptamer-based therapeutics in oncology application is a blockade of protein-protein or receptor-ligand interactions as an antagonist. Accordingly, aptamers have been utilized as antagonists against oncoproteins or their ligands, targeting moieties for drug delivery in multivalent therapeutics. In this section, we specifically focus on therapeutic aptamers with antagonistic functions under pre-clinical investigation for anti-cancer therapy ( Figure 1 and Table 1 ). In addition, antidote aptamers for controlled therapy are also discussed.

3.1. Aptamers as Tools for Cancer Therapy

3.1.1. RNA Aptamer Targeting VEGF

Although the VEGF targeted aptamer pegaptanib is currently approved for use in ophthalmology (see the Clinical Trials section), it was originally designed for use in cancer treatment [ 148 , 149 ]. The cancer treatment strategy of anti-VEGF aptamer is inhibition of VEGF-associated tumor vessel formation by binding to VEGF thus blocking the VEGF/VEGF-R interaction [ 29 ]. Daily treatment of mice bearing human A673 rhabdomyosarcoma cell xenograft tumor with anti-VEGF PEGylated RNA aptamer (EYE001) at a dose of 10 mg/kg inhibited tumor growth by 74% relative to the control [ 149 ]. Recently, an aptamer-antibody hybrid complex has been prepared to improve the pharmacokinetics, using cotinine-specific antibody and cotinine-binding pegaptanib aptamer [ 52 ]. This hybrid complex showed prolongation of half-life in serum to 8.2 h. In an A549 (human lung adenocarcinoma cells) xenograft mouse model, systemic administration of the pegaptanib-antibody complex inhibited tumor angiogenesis and reduced tumor growth (<50%) compared to the human-IgG control mice group. This effect was comparable to that observed for bevacizumab, an anti-VEGF monoclonal antibody.

3.1.2. Aptamers Targeting the Epidermal Growth Factor Receptor (EGFR)

EGFR (ErbB1) is a receptor tyrosine kinase (RTK) that is often mutated and overexpressed in many types of solid tumors, resulting in tumor growth [ 150 ]. Thus, EGFR serves as an excellent therapeutic target, and anti-EGFR antibodies as well as TKI have been widely adopted for clinical use to block the downstream signaling cascade [ 150 ]. Similar to anti-EGFR antibody, the binding of anti-EGFR aptamer to the extracellular domain of EGFR blocks subsequent phosphorylation and downstream signaling, i.e., PI3K/AKT and MAPK signaling [ 29 ]. Several anti-EGFR aptamers have been developed and demonstrated antitumor effect in various cancers (vulvar carcinoma, lung carcinoma, breast cancer, glioblastoma, and epidermoid carcinoma) [ 7 , 8 , 108 , 109 , 110 ]. Esposito et al. reported that CL4, an anti-EGFR 2′-fluoro pyrimidine RNA aptamer, inhibited EGFR-mediated signal pathways, induced apoptosis, and inhibited tumor growth in a mouse xenograft model of human non-small-cell lung cancer (NSCLC) [ 7 ]. Li et al. identified an anti-EGFR 2′-fluoro pyrimidine modified aptamer (E07) that binds both wild-type EGFR as well as EGFR variant III (EGFRvIII), the most common deletion mutant of extracellular domain mutations that precludes ligand binding. The binding of E07 to EGFR expressing A431 epidermoid carcinoma cells led to inhibition of EGFR autophosphorylation and cell proliferation in three-dimensional cultures [ 8 ].

3.1.3. Aptamers Targeting HER2 and HER3

HERs including HER2 (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4) are a part of the EGFR family and transduce growth-promoting signals in response to dimerization of extracellular domains upon ligand binding [ 151 ]. Overexpression of HER2 is observed in approximately 10–15% of breast cancers and currently monoclonal antibody or TKI is used to block its function. Weekly intraperitoneal injection of trimeric DNA anti-HER2 aptamer at a dose of 40 μg exhibited a 2-fold higher tumor inhibitory effect on N87 human gastric cancer cells implanted in CD-1 mice compared to the HER2 monoclonal antibody (Ab431, 160 μg) [ 112 ]. In a recent study, HER3 has been shown to play a role in mediating resistance to HER2 and phosphoinositide 3-kinase (PI3K) pathway-directed therapies due to its feedback regulation via AKT signaling [ 152 ]. As a result, HER3 is being examined as a direct therapeutic target [ 152 ]. The first RNA aptamer against HER3 (A30) has been shown to block interaction between HER3 and its ligand (HRG; heregulin). Binding of HRG disrupts HER3 oligomerization and leads to the formation of signaling-competent heterodimers, preferentially with HER2. Binding of A30 to HER3 inhibited HRG-dependent tyrosine phosphorylation of HER2 and the HRG-induced growth response of MCF7 breast cancer cells in vitro [ 153 ].

3.1.4. DNA Aptamer Targeting Nucleolin

The abundant non-ribosomal protein, nucleolin, which shows abnormally increased cell membrane localization in several types of cancer, interacts with key oncogenes and plays an integral role in cellular proliferation, invasion, and apoptosis [ 100 , 154 , 155 ]. Nucleolin expressed on the cell surface interacts with ligands implicated in cell differentiation, survival, inflammation, angiogenesis, and tumor development [ 156 ]. AS1411 is a guanine quadruplex aptamer that binds to nucleolin, inducing growth inhibition in vitro and in vivo human xenograft models (renal cancer, lung cancer, MX1 breast cancer, and pancreatic cancer) [ 100 ]. Notably, AS1411 was discovered by screening for anti-proliferative activity among antisense oligonucleotides rather than the SELEX method typical in aptamer development [ 100 ]. The underlying mechanism of nucleolin-associated anti-proliferative effect involves binding to cell surface nucleolin, internalization of the aptamer-nucleolin complex, subsequent cell cycle arrest, and apoptosis [ 100 , 155 ]. AS1411 is currently in clinical trials for treatment of leukemia and renal cell carcinoma (see the Clinical Trials section) and is in pre-clinical investigation for other hematologic and solid malignancies. Recent in vitro studies have found that AS1411 displays activity against lymphoma through blockade of secondary targets (nuclear factor-κB and B-cell lymphoma 2) [ 157 , 158 ] and that in combination therapy with doxorubicin it reduced diffuse large B-cell lymphoma (DLBCL) cell survival [ 159 ]. Xenograft tumor models derived from A498 renal cancer, SKMES lung cancer, and MX1 breast cancer cells showed that intravenous administration of AS1411 delays tumor growth [ 100 ]. Moreover, combination therapy with AS1411 and gemcitabine, a chemotherapeutic agent used to treat pancreatic and non–small cell lung cancer in clinical practice, resulted in an increased antitumor effect compared to gemcitabine alone in xenograft model of human pancreatic cancer [ 100 ].

3.1.5. DNA Aptamer Targeting PD-1/PD-L1

Programmed cell death 1 (PD-1; also known as CD279) is expressed in several cell types including T-lymphocytes, specifically CD8 tumor-infiltrating lymphocytes, which are in charge of directly eradicating tumor cells [ 160 ]. The interaction between PD-1 expressed on the surface of T-lymphocytes and PD-L1 expressed on cancer cells leads to an impairment of CD8 cytotoxicity. Prodeus et al. developed a 40 kDa PEGylated DNA aptamer, PEG-MP7, that specifically binds to PD-1, decreases tumor growth, and increases survival in mouse tumor models [ 139 ]. Their study found that PD-L1-mediated suppression of IL-2 secretion was functionally inhibited in primary T-cells treated with the base aptamer MP7 or a known anti-PD-1 antibody, but not control aptamer. Furthermore, an in vivo study using a murine colon cancer model (MC38 cells stably expressing human CEA; MC38.CEA) showed that PEG-MP7 effectively inhibited PD-1: PD-L1 interaction, showing efficacy equal to anti-PD-1 antibody in suppressing PD-L1+ carcinoma cell growth. Additional study by Lai et al. reported the PD-L1 antagonizing DNA aptamer (aptPD-L1) for the blockade of the binding between human PD-1 and PD-L1 [ 140 ]. Repeated intraperitoneal administrations of aptPD-L1 (1.2 mg/kg, 4 times a week) led to significant tumor growth inhibition compared to random-sequence aptamer administration in both the CT26 colon cancer cell line and LL/2 Lewis lung cancer cell line murine syngeneic tumor model mice.

3.1.6. RNA Aptamer Targeting SDF-1 (CXCL12)

CXCL12 (C-X-C motif chemokine ligand 12), also known as SDF-1 (stromal cell-derived factor-1), is a critical chemokine involved in tumor metastasis, angiogenesis, cancer cell homing, and proliferation [ 161 , 162 ]. NOX-A12 is a PEGylated mirror-image RNA aptamer that displays high binding affinity to CXCL12 at a Kd of 0.2 nM [ 104 ]. Through binding to CXCL12, NOX-A12 inhibits signaling on both its receptors, CXCR4 and CXCR7, thus preventing angiogenesis as well as tumor cell proliferation, invasion, and metastasis [ 104 ]. Based on the efficacy of NOX-A12 as a treatment in a pre-clinical study of hematologic malignancies, it is currently in clinical trials for treatment of leukemia (CLL) and multiple myeloma (see Clinical Trials section). In addition, CXCL12 is expressed in the tumor microenvironment mainly by cancer-associated fibroblasts [ 163 ] and has been indicated for resistance to checkpoint inhibitors such as anti-PD-L1 through T-cell exclusion [ 164 ]. Zboralski et al. showed that NOX-A12 broke the immune-privileged status of the tumor microenvironment by paving the way for immune effector cells to enter into the tumor [ 107 ]. In this study, combination of NOX-A12 and anti-PD-1 (NOX-A12: 20 mg/kg s.c., every other day, anti-PD-1: 10 mg/kg i.p. twice weekly) resulted in significant tumor size reduction, superior to either vehicle, anti-PD-1 monotherapy, or NOX-A12 monotherapy in a murine syngeneic CT-26 colon cancer model.

3.1.7. Thioaptamer Targeting E-Selectin

E-selectin is an adhesion molecule expressed on the luminal surface of inflamed blood vessels which mediates hematogenous metastasis by assisting shear-resistant adhesion of circulating tumor cells to the inflamed vessel surface under dynamic blood flow [ 128 ]. An E-selectin antagonistic thioaptamer (ESTA) identified from cell-SELEX demonstrated the ability to inhibit adhesion of circulating cells to E-selectin expressing endothelial cells with binding affinity and IC50 of 47 nM and 63–83 nM, respectively. This accounts for >10,000 times higher affinity and 1000 times lower IC 50 to its natural ligands (sLe x , Kd = 100–2000 uM; IC50 = 100–750 uM) [ 128 ]. Accordingly, a single intravenous injection of ESTA effectively prevented hematogenous metastasis of CD44 high breast cancer cells to a level equal to baseline by abrogating their adhesion to E-selectin-expressing pre-metastatic vascular niches in both syngeneic and xenogeneic forced breast cancer metastasis models [ 129 ]. Additionally, truncated ESTA conjugated with 10 kDa PEG extended its serum half-life and led to improvement of its anti-metastasis activity compared to parental ESTA [ 62 ]. Additionally, twice weekly intravenous administration of PEGylated ESTA at a 128 μg dose was well tolerated; no symptomatic changes in the ALT or AST levels, C3a, C5a complement levels, inflammation, or tissue damage (kidney, lung, or heart) were noted. Based on its E-selectin specific binding ability, ESTA was also used as a targeting moiety for nano- and microparticles [ 165 ]. ESTA conjugation to liposome enhanced tumor targeting in mouse models of breast cancer and conjugation of ESTA to porous silicon microparticles allowed bone marrow targeting in mice [ 166 , 167 ]. This exemplifies the versatile applications of aptamers as therapeutic agents and targeting moieties.

3.1.8. RNA Aptamer Targeting CD40

CD40Apt, a 2-fluoro-RNA aptamer against CD40, has shown antitumor effect on CD40-expressing A20 lymphoma cells in vitro and in vivo. Soldevilla et al. reported that CD40Apt-SMG1-shRNA chimera improved survival of BALB/c mice that were intravenously inoculated with A20 lymphoma cells compared to CD40Apt-control-shRNA or untreated mice [ 145 ].

3.1.9. DNA Aptamer Targeting CTLA-4

Monoclonal antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-1/PD-L1 axis are now a part of routine clinical practice [ 168 ]. Huang et al. reported a novel high-affinity CTLA-4-antagonizing DNA aptamer that promoted lymphocyte proliferation and inhibited tumor growth in a murine syngeneic tumor model with mouse TC-1 lung cancer cells [ 146 ].

3.1.10. RNA/DNA Aptamer Targeting C5a

A synergistic antitumor effect through inhibition of C5a/C5a receptor-1 and PD-1 signaling has been reported. Ajona et al. showed that blockade of PD-1 via RMP1-14 antibody and signaling inhibition of complement C5a/CD5a receptor via AON-D21 L-aptamer, reduced tumor growth and metastasis in syngeneic models of lung cancer. This study further showed a complete reversal of CD8 T-cell exhaustion contributed prolonged survival in mice receiving dual therapy [ 147 ].

3.1.11. Thioaptamer Targeting Annexin A2

Given the central role angiogenesis plays in cancer progression, therapies have sought to target immature tumor blood vessels, yet have only achieved limited efficacy due to treatment induced-hypoxia. Mangala et al. developed a novel approach for the identification of target thioaptanmers using patient-derived endothelial cells [ 169 ]. Thioaptamers specific to tumor associated endothelial cells isolated from ovarian cancer patients were isolated following repeated cycles of negative and positive selection. This unbiased selection method allows for a selection of aptamers that specifically bind to tumor vessels but not to normal vessels. Mass spectrometry data identified a molecular target, the tumor endothelial cell specific membrane protein annexin A2. Treatment with the aptamer/microRNA-inhibitor complex restored tight junction function and improved chemotherapy delivery in orthotopic ovarian cancer mouse models, reducing tumor growth.

3.1.12. Bispecific Aptamers

Bispecific aptamers have been generated to specifically and simultaneously interact with two independent targets. RNA-based bispecific CD44-EpCAM aptamer is capable of blocking CD44 and EpCAM simultaneously by fusing single CD44 and EpCAM aptamers with a double stranded RNA adaptor. Bispecific CD44-EpCAM aptamer suppressed intraperitoneal tumor outgrowth more significantly than individual CD44 and EpCAM aptamers did alone or in combination through enhanced targeting of cancer cells. Bispecific aptamers are well adapted for anti-cancer immunotherapy with minimal toxicity. Co-stimulatory ligand binding of tumor antigen-specific lymphocytes is one immunotherapy approach to boost the antitumor immune response [ 170 ]. However, the use of agonistic antibodies such as anti-4-1BB or anti-CD28 have proven difficult due to activation of the lymphocytes expressing the co-stimulatory receptor. In fact, multi-organ toxicity following the administration of agonistic CD28 antibodies such as TGN1412 led to early termination of clinical trial [ 171 ]. Liver toxicity is a concern with 4-1BB-mediated treatment of cancer [ 172 ]. To alleviate possible adverse effects, bispecific aptamers were developed to bridge between cancer cells and co-stimulatory receptors. For example, bispecific aptamer PSMA-41BB is composed of PSMA and the agonistic 4-1BB aptamers. PSMA binding to cancer cells and 4-1BB binding to the co-stimulatory receptor trigger its activation. Similarly, bispecific aptamers such as VEGF-4-1BB, CD28-MRP1, and CD16a-C-Met have been generated [ 136 , 137 , 138 ]. These bispecific aptamers have shown higher anti-tumor efficacy relative to non-targeted, co-stimulation reagents or their corresponding monoclonal antibody, achieving the same effect with lower toxicity [ 136 , 173 , 174 ].

3.2. Antidote Aptamer for Controlled Therapy

Eradication of malignant cells is currently the main goal of cancer therapies. Therapeutic efficacy and toxicity are often two sides of the same coin and the balance is fundamental to determining therapeutic efficacy. Humanized monoclonal antibodies have shown circulation half-lives as long as several weeks, enabling less frequent drug administration. Such patient-friendly regimens not only improve quality of life, but are also expected to have enhanced anti-tumor efficacy due to continuous drug exposure. However, unanticipated toxicity from such long-circulating drugs may potentially be prolonged unless otherwise inactivated. Antidote aptamers are a strategy to control the action time of therapeutic aptamers using the corresponding complementary sequence. Hybridization with the antidote leads to a conformational change and loss of target binding. Attempts to control drug action time using this method have been confirmed in animal experiments [ 175 , 176 ]. Rusconi et al. showed that coagulation factor IXa antagonistic aptamer Peg-9.3t’s potent anticoagulant activity was efficiently reversed by administration of the complementary oligonucleotide (antidote oligonucleotide 5–2) within 10 min in human plasma. An antidote oligonucleotide for R9D-14T, a RNA aptamer that binds prothrombin and thrombin pro/exosite I, has been shown to swiftly (<2 min) reverse F9D-14T’s anti-coagulation activity in an assay containing human plasma [ 176 ].

4. Clinical Trials of Aptamer Application in Oncology

As previously discussed, renal filtration, nuclease degradation, and safety profile present some of the major hurdles for aptamer therapeutics. However, the degree of such challenges may vary with route of administration as well as the targeted site. The best example of an aptamer therapeutic that has overcome these difficulties is pegaptanib, the first only aptamer to receive FDA marketing approval. In 2004, following almost a decade of development and testing, the efficacy of the RNA aptamer commercially known as Macugen ® (Eyetech Pharmaceuticals, New York, NY, USA) in treating neovascular age-related macular (AMD) degeneration was confirmed by clinical trial [ 177 ]. Through intravitreous administration every 6 weeks over a 48-week course, pegaptanib acts as an antagonist to vascular endothelial growth factor (VEGF), which plays a role in pathologic angiogenesis. In addition to abnormal neovascularization, VEGF contributes to increased vascular permeability and other effects important not only in the development of macular degeneration, but also cancer [ 9 , 178 , 179 ]. Given the significant role VEGF plays in tumors it was initially thought that pegaptanib may display anti-cancer properties as well. Unfortunately, preclinical models failed to substantiate this hypothesis and the drug has not been tested in a clinical trial for oncology application [ 29 ]. The bioavailability of intravitrious injections may contribute to the difference in pegaptanib’s efficacy in AMD and solid tumors, since the former route does not necessitate extended circulation time to reach the target as it does in tumors. Further preclinical studies, however, are underway to address novel ways of improving the biostability of aptamers like pegaptanib [ 52 ].

To date, two therapeutic aptamers have made successful transition to clinical trials for oncology, although several ongoing trials have incorporated the development of targeted aptamers for either detection or monitoring into their study design. The first aptamer in clinical trials for cancer treatment was AS1411, a nucleolin-targeting DNA aptamer [ 100 ]. Its unique G-rich quadruplex structure as well as pegylation aid the pharmacokinetic profile of AS1411, providing nuclease evasion and an extended half-life [ 100 ]. Two clinical trials of AS1411 have assessed safety and efficacy in advanced solid tumors and renal cell carcinoma, respectively ( NCT00881244 [ 180 ] and NCT00740441 [ 181 ]), while a third examined AS1411 in treatment of acute myeloid leukemia (AML) ( NCT00512083 [ 182 ]). In its initial dose-escalation Phase I clinical study, AS1411 was administered as a continuous intravenous infusion at doses ranging from 1–40 mg/kg/day for 4 to 7 days in up to two cycles of treatment for patients with advanced solid tumors and was found to be well tolerated without serious side effects. Given the promising results of initial clinical assessment, a Phase II trial was conducted in patients with metastatic refractory renal cell carcinoma (RCC), but found the drug to have limited activity in unselected patients, indicating the need for biomarkers for AS1411 responsive tumors. Pre-clinical studies demonstrating that AS1411 targets cell-membrane nucleolin in leukemia cells [ 183 ] and results in cell death for acute myeloid leukemia (AML) cell lines [ 184 ] indicated its efficacy in hematologic malignancies as well. Another Phase II trial examined the effect of combination therapy with AS1411 and high-dose cytarabine in relapsed/refractory AML patients and found improved response rates among patients receiving combination therapy with continuous infusion of either 10 or 40 mg/kg/day dosing of AS1411 when compared to the control cytarabine only group [ 185 ]. Several pre-clinical models are also investigating its role as a potential transport mechanism for other anti-cancer drugs (See the under investigation section), possibly expanding its impact from hematologic malignancies to solid as well.

The second therapeutic aptamer to launch clinical trials for cancer is NOX-A12 (Olaptesed Pegol, NOXXON), an antagonist of the chemokine CXCL12 (or SDF1). Thus far, NOX-A12 has only completed clinical trials for hematologic malignancies, although a new two-part trial ( NCT03168139 [ 186 ]) is currently recruiting patients with colorectal or pancreatic cancer. NOX-A12 is an L-form RNA aptamer (or Spiegelmer) whose inverted stereochemistry provides nuclear resistance, while PEGylation at the 3′-terminus provides further enhancement of its pharmacokinetic parameters. Pre-clinical models showed that NOX-A12 mobilized white blood cells, hematopoietic stem cells, and progenitor cells in the peripheral blood of mice and healthy human volunteers [ 104 ] and Phase I trials ( NCT00976378 [ 187 ] and NCT01194934 [ 188 ]) established its safety profile in healthy volunteers. Pre-clinical models demonstrated that co-treatment of multiple myeloma (MM) cells with NOX-A12 inhibited chemotaxis of MM to bone marrow, inhibiting cell adhesion-mediated drug resistance and sensitizing them to chemotherapy [ 189 ]. NOX-A12 also decreased BM niche microenvironment receptivity to MM cells, halting an essential step in disease progression in mouse models [ 190 ]. Thus, a Phase II trial ( NCT01521533 [ 191 ]) comparing single dose intravenous injections of NOX-A12 alone and in combination with bortezomib and dexamethasone (VD) in multiple myeloma (MM) patients who had received previous treatment was performed. Results from this trial indicated that NOX-A12 enhanced the efficacy of VD treatment without increasing treatment toxicity [ 192 ]. Pre-clinical models in chronic lymphocytic leukemia (CLL) also showed that NOX-A12 effectively prevented chemotaxis of cancer cells towards CXCL12 and sensitized the cells to chemotherapies in bone marrow stem cell (BMSC) co-cultures [ 106 ]. Phase II study ( NCT01486797 [ 193 ]) testing the efficacy of NOX-A12 in combination with bendamustine and rituximab chemotherapy in patients with relapsed CLL also found improved overall response rates as well as increasing rates of remission in patients treated with NOX-A12 [ 194 ]. The aptamer is currently in the recruitment stage of a two-part, phase I/II clinical trial of testing the drug in combination with pembrolizumab in metastatic colorectal and pancreatic cancer ( NCT03168139 [ 186 ]).

5. Conclusions and Future Perspectives

In the era of personalized medicine, targeted therapy has become an integral part of cancer treatment in conjunction with conventional chemo- and radiotherapy, and many molecularly targeted drugs are under investigation and in the drug development pipeline [ 195 ]. Aptamers have evolved rapidly in the past 10 years as evidenced by the steep increase in related peer-review publications and US patents, and have been highlighted as the next generation of anti-cancer drug owing to their unique characteristics (high affinity binding, low immunogenicity, ease of synthesis, and chemical modification). A range of molecules involved in tumor progression and metastasis, present at different sites (i.e., circulation, cancer cell, tumor stroma, tumor associated vessel, and pre-metastic vascular niche), have been targeted by aptamers. Pre-clinical investigations of aptamers have shown promising efficacies as well as safety profiles. Creative chemistry has effectively addressed the primary challenges of aptamer therapeutics. Mounting evidence supports the competencies of aptamers for clinical utility in treating cancer, and currently, two anti-cancer aptamers have launched clinical trials. As safe, high-affinity therapeutics, aptamers present an exceptional opportunity to make personalized medicine a reality for more patients with cancer.

Acknowledgments

This work was supported by the National Institutes of Health (1R01CA160271-01A1 to T.T).

Conflicts of Interest

The authors declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References

1. Lakhin A.V. Tarantul V.Z. Gening L.V. Aptamers: Problems, solutions and prospects Acta Naturae 2013 5 34 43 24455181 PMC3890987

2. Gewirtz A.M. Oligonucleotide therapeutics: Clothing the emperor Curr. Opin. Mol. Ther. 1999 1 297 306 11713794

3. Brody E.N. Gold L. Aptamers as therapeutic and diagnostic agents J. Biotechnol. 2000 74 5 13 10.1016/S1389-0352(99)00004-5 10943568

4. Yen H.-Y. Liu Y.-C. Chen N.-Y. Tsai C.-F. Wang Y.-T. Chen Y.-J. Hsu T.-L. Yang P.-C. Wong C.-H. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition Proc. Natl. Acad. Sci. USA 2015 112 6955 6960 10.1073/pnas.1507329112 25971727 PMC4460513

5. Yun C.H. Boggon T.J. Li Y. Woo M.S. Greulich H. Meyerson M. Eck M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 2007 11 217 227 10.1016/j.ccr.2006.12.017 17349580 PMC1939942

6. Li S. Schmitz K.R. Jeffrey P.D. Wiltzius J.J. Kussie P. Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 2005 7 301 311 10.1016/j.ccr.2005.03.003 15837620

7. Esposito C.L. Passaro D. Longobardo I. Condorelli G. Marotta P. Affuso A. de Franciscis V. Cerchia L. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death PLoS ONE 2011 6 e24071 10.1371/journal.pone.0024071 21915281 PMC3167817

8. Li N. Nguyen H.H. Byrom M. Ellington A.D. Inhibition of cell proliferation by an anti-EGFR aptamer PLoS ONE 2011 6 e20299 10.1371/journal.pone.0020299 21687663 PMC3110755

9. Ruckman J. Green L.S. Beeson J. Waugh S. Gillette W.L. Henninger D.D. Claesson-Welsh L. Janjic N. 2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J. Biol. Chem. 1998 273 20556 20567 10.1074/jbc.273.32.20556 9685413

10. Khati M. Schuman M. Ibrahim J. Sattentau Q. Gordon S. James W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers J. Virol. 2003 77 12692 12698 10.1128/JVI.77.23.12692-12698.2003 14610191 PMC262555

11. Layzer J.M. McCaffrey A.P. Tanner A.K. Huang Z. Kay M.A. Sullenger B.A. In vivo activity of nuclease-resistant siRNAs RNA 2004 10 766 771 10.1261/rna.5239604 15100431 PMC1370566

12. Jellinek D. Green L.S. Bell C. Lynott C.K. Gill N. Vargeese C. Kirschenheuter G. McGee D.P. Abesinghe P. Pieken W.A. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor Biochemistry 1995 34 11363 11372 10.1021/bi00036a009 7547864

13. Yan X. Gao X. Zhang Z. Isolation and characterization of 2′-amino-modified RNA aptamers for human TNFα Genom. Proteom. Bioinform. 2004 2 32 42 10.1016/S1672-0229(04)02005-4 PMC5172437 15629041

14. Padilla R. Sousa R. A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs Nucleic Acids Res. 2002 30 e138 10.1093/nar/gnf138 12490729 PMC140087

15. Dellafiore M.A. Montserrat J.M. Iribarren A.M. Modified nucleoside triphosphates for in vitro selection techniques Front. Chem. 2016 4 18 10.3389/fchem.2016.00018 27200340 PMC4854868

16. Volk D.E. Lokesh G.L.R. Development of phosphorothioate DNA and DNA thioaptamers Biomedicines 2017 5 41 10.3390/biomedicines5030041 28703779 PMC5618299

17. Clercq E.D. Eckstein F. Merigan T.C. Interferon induction increased through chemical modification of a synthetic polyribonucleotide Science 1969 165 1137 1139 10.1126/science.165.3898.1137 5801596

18. Kruspe S. Giangrande P.H. Aptamer-siRNA chimeras: Discovery, progress, and future prospects Biomedicines 2017 5 45 10.3390/biomedicines5030045 28792479 PMC5618303

19. Bruno J.G. A review of therapeutic aptamer conjugates with emphasis on new approaches Pharmaceuticals 2013 6 340 357 10.3390/ph6030340 24276022 PMC3816688

20. Ozalp V.C. Kavruk M. Dilek O. Bayrac A.T. Aptamers: Molecular tools for medical diagnosis Curr. Top. Med. Chem. 2015 15 1125 1137 10.2174/1568026615666150413154233 25866272

21. Seo H.B. Gu M.B. Aptamer-based sandwich-type biosensors J. Biol. Eng. 2017 11 11 10.1186/s13036-017-0054-7 28293287 PMC5346835

22. Shrivastava S. Jadon N. Jain R. Next-generation polymer nanocomposite-based electrochemical sensors and biosensors: A review TrAC Trends Anal. Chem. 2016 82 55 67 10.1016/j.trac.2016.04.005

23. Ma H. Liu J. Ali M.M. Mahmood M.A. Labanieh L. Lu M. Iqbal S.M. Zhang Q. Zhao W. Wan Y. Nucleic acid aptamers in cancer research, diagnosis and therapy Chem. Soc. Rev. 2015 44 1240 1256 10.1039/C4CS00357H 25561050

24. Mustonen E.K. Palomaki T. Pasanen M. Oligonucleotide-based pharmaceuticals: Non-clinical and clinical safety signals and non-clinical testing strategies Regul. Toxicol. Pharmacol. 2017 90 328 341 10.1016/j.yrtph.2017.09.028 28966105

25. Ouyang W. Yu Z. Zhao X. Lu S. Wang Z. Aptamers in hematological malignancies and their potential therapeutic implications Crit. Rev. Oncol. Hematol. 2016 106 108 117 10.1016/j.critrevonc.2016.08.003 27637356

26. Parashar A. Aptamers in therapeutics J. Clin. Diagn. Res. 2016 10 BE01-06 10.7860/JCDR/2016/18712.7922 27504277 PMC4963637

27. Poolsup S. Kim C.Y. Therapeutic applications of synthetic nucleic acid aptamers Curr. Opin. Biotechnol. 2017 48 180 186 10.1016/j.copbio.2017.05.004 28582756

28. Yazdian-Robati R. Arab A. Ramezani M. Abnous K. Taghdisi S.M. Application of aptamers in treatment and diagnosis of leukemia Int. J. Pharm. 2017 529 44 54 10.1016/j.ijpharm.2017.06.058 28648578

29. Zhou G. Wilson G. Hebbard L. Duan W. Liddle C. George J. Qiao L. Aptamers: A promising chemical antibody for cancer therapy Oncotarget 2016 7 13446 13463 10.18632/oncotarget.7178 26863567 PMC4924653

30. Zhu H. Li J. Zhang X.B. Ye M. Tan W. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy ChemMedChem 2015 10 39 45 10.1002/cmdc.201402312 25277749

31. Robbie G.J. Criste R. Dall’Acqua W.F. Jensen K. Patel N.K. Losonsky G.A. Griffin M.P. A novel investigational fc-modified humanized monoclonal antibody, motavizumab-yte, has an extended half-life in healthy adults Antimicrob. Agents Chemother. 2013 57 6147 6153 10.1128/AAC.01285-13 24080653 PMC3837853

32. Griffin L.C. Tidmarsh G.F. Bock L.C. Toole J.J. Leung L.L. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits Blood 1993 81 3271 3276 8507864

33. Tucker C.E. Chen L.S. Judkins M.B. Farmer J.A. Gill S.C. Drolet D.W. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (nx1838) in rhesus monkeys J. Chromatogr. B Biomed. Sci. Appl. 1999 732 203 212 10.1016/S0378-4347(99)00285-6 10517237

34. Drolet D.W. Nelson J. Tucker C.E. Zack P.M. Nixon K. Bolin R. Judkins M.B. Farmer J.A. Wolf J.L. Gill S.C. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (nx1838) following injection into the vitreous humor of rhesus monkeys Pharm. Res. 2000 17 1503 1510 10.1023/A:1007657109012 11303960

35. Siddiqui M.A. Keating G.M. Pegaptanib: In exudative age-related macular degeneration Drugs 2005 65 1571 1577 discussion 1578–1579 10.2165/00003495-200565110-00010 16033295

36. Derbyshire N. White S.J. Bunka D.H. Song L. Stead S. Tarbin J. Sharman M. Zhou D. Stockley P.G. Toggled RNA aptamers against aminoglycosides allowing facile detection of antibiotics using gold nanoparticle assays Anal. Chem. 2012 84 6595 6602 10.1021/ac300815c 22793869 PMC3413241

37. Kuwahara M. Sugimoto N. Molecular evolution of functional nucleic acids with chemical modifications Molecules 2010 15 5423 5444 10.3390/molecules15085423 20714306 PMC6257756

38. Lebars I. Richard T. Di Primo C. Toulme J.J. LNA derivatives of a kissing aptamer targeted to the trans -activating responsive RNA element of hiv-1 Blood Cells Mol. Dis. 2007 38 204 209 10.1016/j.bcmd.2006.11.008 17300966

39. Hernandez F.J. Stockdale K.R. Huang L. Horswill A.R. Behlke M.A. McNamara J.O. 2nd Degradation of nuclease-stabilized RNA oligonucleotides in mycoplasma-contaminated cell culture media Nucleic Acid Ther. 2012 22 58 68 10.1089/nat.2011.0316 22229275 PMC3318257

40. Thiviyanathan V. Somasunderam A.D. Gorenstein D.G. Combinatorial selection and delivery of thioaptamers Biochem. Soc. Trans. 2007 35 50 52 10.1042/BST0350050 17233599

41. Volk D.E. Yang X. Fennewald S.M. King D.J. Bassett S.E. Venkitachalam S. Herzog N. Luxon B.A. Gorenstein D.G. Solution structure and design of dithiophosphate backbone aptamers targeting transcription factor nf-kappab Bioorg. Chem. 2002 30 396 419 10.1016/S0045-2068(02)00510-2 12642125

42. Maasch C. Buchner K. Eulberg D. Vonhoff S. Klussmann S. Physicochemical stability of NOX-E36, a 40mer L-RNA (spiegelmer) for therapeutic applications Nucleic Acids Symp. Ser. 2008 52 61 62 10.1093/nass/nrn031 18776253

43. Pfander S. Fiammengo R. Kirin S.I. Metzler-Nolte N. Jaschke A. Reversible site-specific tagging of enzymatically synthesized RNAs using aldehyde-hydrazine chemistry and protease-cleavable linkers Nucleic Acids Res. 2007 35 e25 10.1093/nar/gkl1110 17259220 PMC1851632

44. Nitsche A. Kurth A. Dunkhorst A. Panke O. Sielaff H. Junge W. Muth D. Scheller F. Stocklein W. Dahmen C. One-step selection of vaccinia virus-binding DNA aptamers by monolex BMC Biotechnol. 2007 7 48 10.1186/1472-6750-7-48 17697378 PMC1994675

45. Di Giusto D.A. Knox S.M. Lai Y. Tyrelle G.D. Aung M.T. King G.C. Multitasking by multivalent circular DNA aptamers Chembiochem 2006 7 535 544 10.1002/cbic.200500316 16482500

46. Mori Y. Nakamura Y. Ohuchi S. Inhibitory RNA aptamer against sp6 RNA polymerase Biochem. Biophys. Res. Commun. 2012 420 440 443 10.1016/j.bbrc.2012.03.014 22426482

47. Guo P. The emerging field of RNA nanotechnology Nat. Nanotechnol. 2010 5 833 842 10.1038/nnano.2010.231 21102465 PMC3149862

48. Burmeister P.E. Lewis S.D. Silva R.F. Preiss J.R. Horwitz L.R. Pendergrast P.S. McCauley T.G. Kurz J.C. Epstein D.M. Wilson C. Direct in vitro selection of a 2′- O -methyl aptamer to VEGF Chem. Biol. 2005 12 25 33 10.1016/j.chembiol.2004.10.017 15664512

49. Rusconi C.P. Roberts J.D. Pitoc G.A. Nimjee S.M. White R.R. Quick G. Jr. Scardino E. Fay W.P. Sullenger B.A. Antidote-mediated control of an anticoagulant aptamer in vivo Nat. Biotechnol. 2004 22 1423 1428 10.1038/nbt1023 15502817

50. Lee C.H. Lee S.H. Kim J.H. Noh Y.H. Noh G.J. Lee S.W. Pharmacokinetics of a cholesterol-conjugated aptamer against the hepatitis C virus (HCV) NS5B protein Mol. Ther. Nucleic Acids 2015 4 e254 10.1038/mtna.2015.30 26440598 PMC4881758

51. Dougan H. Lyster D.M. Vo C.V. Stafford A. Weitz J.I. Hobbs J.B. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood Nucl. Med. Biol. 2000 27 289 297 10.1016/S0969-8051(99)00103-1 10832086

52. Heo K. Min S.W. Sung H.J. Kim H.G. Kim H.J. Kim Y.H. Choi B.K. Han S. Chung S. Lee E.S. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies J. Control. Release 2016 229 1 9 10.1016/j.jconrel.2016.03.006 26956592

53. Kim Y. Dennis D.M. Morey T. Yang L. Tan W. Engineering dendritic aptamer assemblies as superior inhibitors of protein function Chem. Asian J. 2010 5 56 59 10.1002/asia.200900421 19967736

54. Musumeci D. Montesarchio D. Polyvalent nucleic acid aptamers and modulation of their activity: A focus on the thrombin binding aptamer Pharmacol. Ther. 2012 136 202 215 10.1016/j.pharmthera.2012.07.011 22850531

55. Soule E.E. Bompiani K.M. Woodruff R.S. Sullenger B.A. Targeting two coagulation cascade proteases with a bivalent aptamer yields a potent and antidote-controllable anticoagulant Nucleic Acid Ther. 2016 26 1 9 10.1089/nat.2015.0565 26584417 PMC4753633

56. Willis M.C. Collins B.D. Zhang T. Green L.S. Sebesta D.P. Bell C. Kellogg E. Gill S.C. Magallanez A. Knauer S. Liposome-anchored vascular endothelial growth factor aptamers Bioconj. Chem. 1998 9 573 582 10.1021/bc980002x 9736491

57. Zhou J. Soontornworajit B. Martin J. Sullenger B.A. Gilboa E. Wang Y. A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling Macromol. Biosci. 2009 9 831 835 10.1002/mabi.200900046 19434675

58. Chen L. Rashid F. Shah A. Awan H.M. Wu M. Liu A. Wang J. Zhu T. Luo Z. Shan G. The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation Proc. Natl. Acad. Sci. USA 2015 112 10002 10007 10.1073/pnas.1502159112 26216949 PMC4538674

59. Milla P. Dosio F. Cattel L. Pegylation of proteins and liposomes: A powerful and flexible strategy to improve the drug delivery Curr. Drug Metab. 2012 13 105 119 10.2174/138920012798356934 21892917

60. Turecek P.L. Bossard M.J. Schoetens F. Ivens I.A. Pegylation of biopharmaceuticals: A review of chemistry and nonclinical safety information of approved drugs J. Pharm. Sci. 2016 105 460 475 10.1016/j.xphs.2015.11.015 26869412

61. Pasut G. Veronese F.M. State of the art in pegylation: The great versatility achieved after forty years of research J. Control. Release 2012 161 461 472 10.1016/j.jconrel.2011.10.037 22094104

62. Morita Y. Kamal M. Kang S.A. Zhang R. Lokesh G.L. Thiviyanathan V. Hasan N. Woo S. Zhao D. Leslie M. E-selectin targeting pegylated-thioaptamer prevents breast cancer metastases Mol. Ther. Nucleic Acids 2016 5 e399 10.1038/mtna.2016.103 27959340

63. Ganson N.J. Povsic T.J. Sullenger B.A. Alexander J.H. Zelenkofske S.L. Sailstad J.M. Rusconi C.P. Hershfield M.S. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer J. Allergy Clin. Immunol. 2016 137 1610 1613 10.1016/j.jaci.2015.10.034 26688515 PMC5819876

64. Keefe A.D. Pai S. Ellington A. Aptamers as therapeutics Nat. Rev. Drug Discov. 2010 9 537 550 10.1038/nrd3141 20592747 PMC7097324

65. Stessl M. Noe C.R. Winkler J. Off-Target Effects and Safety Aspects of Phosphorothioate Oligonucleotides Springer Berlin/Heidelberg, Germany 2012

66. Geary R.S. Yu R.Z. Watanabe T. Henry S.P. Hardee G.E. Chappell A. Matson J. Sasmor H. Cummins L. Levin A.A. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′- O -(2-methoxyethyl) modified antisense oligonucleotide: Comparison across species Drug Metab. Dispos. 2003 31 1419 1428 10.1124/dmd.31.11.1419 14570775

67. Farman C.A. Kornbrust D.J. Oligodeoxynucleotide studies in primates: Antisense and immune stimulatory indications Toxicol. Pathol. 2003 31 Suppl. 1 119 122 12597439 10.1080/01926230390174995

68. Goebl N. Berridge B. Wroblewski V.J. Brown-Augsburger P.L. Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in tissue sections Toxicol. Pathol. 2007 35 541 548 10.1080/01926230701338958 17562487

69. Sarmiento U.M. Perez J.R. Becker J.M. Narayanan R. In vivo toxicological effects of rel a antisense phosphorothioates in CD-1 mice Antisense Res. Dev. 1994 4 99 107 10.1089/ard.1994.4.99 7950306

70. Henry S.P. Zuckerman J.E. Rojko J. Hall W.C. Harman R.J. Kitchen D. Crooke S.T. Toxicological properties of several novel oligonucleotide analogs in mice Anticancer Drug Des. 1997 12 1 14 9051110

71. Bouchard P.R. Hutabarat R.M. Thompson K.M. Discovery and development of therapeutic aptamers Annu. Rev. Pharmacol. Toxicol. 2010 50 237 257 10.1146/annurev.pharmtox.010909.105547 20055704

72. Henry S.P. Taylor J. Midgley L. Levin A.A. Kornbrust D.J. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice Antisense Nucleic Acid Drug Dev. 1997 7 473 481 10.1089/oli.1.1997.7.473 9361906

73. Henry S.P. Templin M.V. Gillett N. Rojko J. Levin A.A. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1 Toxicol. Pathol. 1999 27 95 100 10.1177/019262339902700117 10367680

74. Kang S.A. Tsolmon B. Mann A.P. Zheng W. Zhao L. Zhao Y.D. Volk D.E. Lokesh G.L. Morris L. Gupta V. Safety evaluation of intravenously administered mono-thioated aptamer against e-selectin in mice Toxicol. Appl. Pharmacol. 2015 287 86 92 10.1016/j.taap.2015.05.011 26048585 PMC4966538

75. Goel S. Desai K. Macapinlac M. Wadler S. Goldberg G. Fields A. Einstein M. Volterra F. Wong B. Martin R. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase a R1α in patients with advanced solid cancers Investig. New Drugs 2006 24 125 134 10.1007/s10637-006-2378-x 16683205

76. Akdim F. Stroes E.S. Sijbrands E.J. Tribble D.L. Trip M.D. Jukema J.W. Flaim J.D. Su J. Yu R. Baker B.F. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J. Am. Coll. Cardiol. 2010 55 1611 1618 10.1016/j.jacc.2009.11.069 20378080

77. Wong E. Goldberg T. Mipomersen (kynamro): A novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia Pharm. Ther. 2014 39 119 122 PMC3956393 24669178

78. Raal F.J. Santos R.D. Blom D.J. Marais A.D. Charng M.J. Cromwell W.C. Lachmann R.H. Gaudet D. Tan J.L. Chasan-Taber S. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of ldl cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial Lancet 2010 375 998 1006 10.1016/S0140-6736(10)60284-X 20227758

79. McGowan M.P. Tardif J.C. Ceska R. Burgess L.J. Soran H. Gouni-Berthold I. Wagener G. Chasan-Taber S. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS ONE 2012 7 e49006 10.1371/journal.pone.0049006 23152839 PMC3496741

80. Stein E.A. Dufour R. Gagne C. Gaudet D. East C. Donovan J.M. Chin W. Tribble D.L. McGowan M. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: Results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 2012 126 2283 2292 10.1161/CIRCULATIONAHA.112.104125 23060426

81. Sheehan J.P. Lan H.C. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex Blood 1998 92 1617 1625 9716589

82. Yacyshyn B.R. Bowen-Yacyshyn M.B. Jewell L. Tami J.A. Bennett C.F. Kisner D.L. Shanahan W.R. Jr. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease Gastroenterology 1998 114 1133 1142 10.1016/S0016-5085(98)70418-4 9609749

83. Henry S.P. Beattie G. Yeh G. Chappel A. Giclas P. Mortari A. Jagels M.A. Kornbrust D.J. Levin A.A. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide Int. Immunopharmacol. 2002 2 1657 1666 10.1016/S1567-5769(02)00142-X 12469940

84. Henry S.P. Jagels M.A. Hugli T.E. Manalili S. Geary R.S. Giclas P.C. Levin A.A. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum Nucleic Acid Ther. 2014 24 326 335 10.1089/nat.2014.0491 25093529

85. Avci-Adali M. Steinle H. Michel T. Schlensak C. Wendel H.P. Potential capacity of aptamers to trigger immune activation in human blood PLoS ONE 2013 8 e68810 10.1371/journal.pone.0068810 23935890 PMC3720859

86. Weber C. Muller C. Podszuweit A. Montino C. Vollmer J. Forsbach A. Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects) Immunology 2012 136 64 77 10.1111/j.1365-2567.2012.03559.x 22260507 PMC3372758

87. Akira S. Uematsu S. Takeuchi O. Pathogen recognition and innate immunity Cell 2006 124 783 801 10.1016/j.cell.2006.02.015 16497588

88. Krieg A.M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides Biochim. Biophys. Acta 1999 1489 107 116 10.1016/S0167-4781(99)00147-5 10807001

89. Krieg A.M. Therapeutic potential of toll-like receptor 9 activation Nat. Rev. Drug Discov. 2006 5 471 484 10.1038/nrd2059 16763660

90. Klinman D.M. Yi A.K. Beaucage S.L. Conover J. Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma Proc. Natl. Acad. Sci. USA 1996 93 2879 2883 10.1073/pnas.93.7.2879 8610135 PMC39727

91. Krieg A.M. Yi A.K. Matson S. Waldschmidt T.J. Bishop G.A. Teasdale R. Koretzky G.A. Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation Nature 1995 374 546 549 10.1038/374546a0 7700380

92. Foy J.W. Rittenhouse K. Modi M. Patel M. Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit J. Ocul. Pharmacol. Ther. 2007 23 452 466 10.1089/jop.2006.0149 17900226

93. Cerchia L. Esposito C.L. Camorani S. Catuogno S. Franciscis V. Coupling aptamers to short interfering RNAs as therapeutics Pharmaceuticals 2011 4 1434 1449 10.3390/ph4111434 27721331 PMC4060133

94. Armstrong J.K. Hempel G. Koling S. Chan L.S. Fisher T. Meiselman H.J. Garratty G. Antibody against poly(ethylene glycol) adversely affects peg-asparaginase therapy in acute lymphoblastic leukemia patients Cancer 2007 110 103 111 10.1002/cncr.22739 17516438

95. Hershfield M.S. Ganson N.J. Kelly S.J. Scarlett E.L. Jaggers D.A. Sundy J.S. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients Arthritis Res. Ther. 2014 16 R63 10.1186/ar4500 24602182 PMC4060462

96. Akiyama H. Kachi S. Silva R.L. Umeda N. Hackett S.F. McCauley D. McCauley T. Zoltoski A. Epstein D.M. Campochiaro P.A. Intraocular injection of an aptamer that binds PDGF-B: A potential treatment for proliferative retinopathies J. Cell. Physiol. 2006 207 407 412 10.1002/jcp.20583 16419035

97. Sennino B. Falcon B.L. McCauley D. Le T. McCauley T. Kurz J.C. Haskell A. Epstein D.M. McDonald D.M. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102 Cancer Res. 2007 67 7358 7367 10.1158/0008-5472.CAN-07-0293 17671206 PMC4422164

98. Kaur H. Li J.J. Bay B.H. Yung L.Y. Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells PLoS ONE 2013 8 e50964 10.1371/journal.pone.0050964 23341879 PMC3547035

99. Gantenbein A.R. Sarikaya H. Riederer F. Goadsby P.J. Postoperative hemicrania continua-like headache—A case series J. Headache Pain 2015 16 526 10.1186/s10194-015-0526-4 25968100 PMC4429110

100. Ireson C.R. Kelland L.R. Discovery and development of anticancer aptamers Mol. Cancer Ther. 2006 5 2957 2962 10.1158/1535-7163.MCT-06-0172 17172400

101. Bates P.J. Laber D.A. Miller D.M. Thomas S.D. Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer Exp. Mol. Pathol. 2009 86 151 164 10.1016/j.yexmp.2009.01.004 19454272 PMC2716701

102. Mongelard F. Bouvet P. As-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia Curr. Opin. Mol. Ther. 2010 12 107 114 20140822

103. Fan X. Sun L. Li K. Yang X. Cai B. Zhang Y. Zhu Y. Ma Y. Guan Z. Wu Y. The bioactivity of d -/ l -isonucleoside- and 2′-deoxyinosine-incorporated aptamer AS1411s including DNA replication/microrna expression Mol. Ther. Nucleic Acids 2017 9 218 229 10.1016/j.omtn.2017.09.010 29246300 PMC5651494

104. Vater A. Sahlmann J. Kroger N. Zollner S. Lioznov M. Maasch C. Buchner K. Vossmeyer D. Schwoebel F. Purschke W.G. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12 Clin. Pharmacol. Ther. 2013 94 150 157 10.1038/clpt.2013.58 23588307

105. Liu S.C. Alomran R. Chernikova S.B. Lartey F. Stafford J. Jang T. Merchant M. Zboralski D. Zollner S. Kruschinski A. Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats Neuro Oncol. 2014 16 21 28 10.1093/neuonc/not149 24335554 PMC3870826

106. Hoellenriegel J. Zboralski D. Maasch C. Rosin N.Y. Wierda W.G. Keating M.J. Kruschinski A. Burger J.A. The spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization Blood 2014 123 1032 1039 10.1182/blood-2013-03-493924 24277076 PMC4123413

107. Zboralski D. Hoehlig K. Eulberg D. Fromming A. Vater A. Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade Cancer Immunol. Res. 2017 5 950 956 10.1158/2326-6066.CIR-16-0303 28963140

108. Wan Y. Tamuly D. Allen P.B. Kim Y.T. Bachoo R. Ellington A.D. Iqbal S.M. Proliferation and migration of tumor cells in tapered channels Biomed. Microdevices 2013 15 635 643 10.1007/s10544-012-9721-0 23104156 PMC3578089

109. Buerger C. Nagel-Wolfrum K. Kunz C. Wittig I. Butz K. Hoppe-Seyler F. Groner B. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with STAT3 activation and inhibit the growth of tumor cells J. Biol. Chem. 2003 278 37610 37621 10.1074/jbc.M301629200 12842895

110. Wang D.L. Song Y.L. Zhu Z. Li X.L. Zou Y. Yang H.T. Wang J.J. Yao P.S. Pan R.J. Yang C.J. Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity Biochem. Biophys. Res. Commun. 2014 453 681 685 10.1016/j.bbrc.2014.09.023 25242523

111. Kim M.Y. Jeong S. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells Nucleic Acid Ther. 2011 21 173 178 10.1089/nat.2011.0283 21749294 PMC3198746

112. Mahlknecht G. Maron R. Mancini M. Schechter B. Sela M. Yarden Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth Proc. Natl. Acad. Sci. USA 2013 110 8170 8175 10.1073/pnas.1302594110 23630281 PMC3657787

113. Lee Y.J. Kim I.S. Park S.A. Kim Y. Lee J.E. Noh D.Y. Kim K.T. Ryu S.H. Suh P.G. Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis Mol. Ther. 2013 21 1004 1013 10.1038/mt.2013.30 23511245 PMC3666628

114. Hicke B.J. Stephens A.W. Gould T. Chang Y.F. Lynott C.K. Heil J. Borkowski S. Hilger C.S. Cook G. Warren S. Tumor targeting by an aptamer J. Nucl. Med. 2006 47 668 678 16595502

115. Daniels D.A. Chen H. Hicke B.J. Swiderek K.M. Gold L. A tenascin-c aptamer identified by tumor cell selex: Systematic evolution of ligands by exponential enrichment Proc. Natl. Acad. Sci. USA 2003 100 15416 15421 10.1073/pnas.2136683100 14676325 PMC307582

116. Hicke B.J. Marion C. Chang Y.F. Gould T. Lynott C.K. Parma D. Schmidt P.G. Warren S. Tenascin-C aptamers are generated using tumor cells and purified protein J. Biol. Chem. 2001 276 48644 48654 10.1074/jbc.M104651200 11590140

117. Zamay T.N. Kolovskaya O.S. Glazyrin Y.E. Zamay G.S. Kuznetsova S.A. Spivak E.A. Wehbe M. Savitskaya A.G. Zubkova O.A. Kadkina A. DNA-aptamer targeting vimentin for tumor therapy in vivo Nucleic Acid Ther. 2014 24 160 170 10.1089/nat.2013.0471 24410722 PMC3962644

118. Lee Y.J. Han S.R. Kim N.Y. Lee S.H. Jeong J.S. Lee S.W. An RNA aptamer that binds carcinoembryonic antigen inhibits hepatic metastasis of colon cancer cells in mice Gastroenterology 2012 143 155 165 10.1053/j.gastro.2012.03.039 22465431

119. Ojima A. Matsui T. Maeda S. Takeuchi M. Inoue H. Higashimoto Y. Yamagishi S. DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice Lab. Investig. 2014 94 422 429 10.1038/labinvest.2014.5 24514068

120. Mi J. Zhang X. Rabbani Z.N. Liu Y. Reddy S.K. Su Z. Salahuddin F.K. Viles K. Giangrande P.H. Dewhirst M.W. RNA aptamer-targeted inhibition of NF-κB suppresses non-small cell lung cancer resistance to doxorubicin Mol. Ther. 2008 16 66 73 10.1038/sj.mt.6300320 17912235

121. Cerchia L. Esposito C.L. Camorani S. Rienzo A. Stasio L. Insabato L. Affuso A. de Franciscis V. Targeting AXL with an high-affinity inhibitory aptamer Mol. Ther. 2012 20 2291 2303 10.1038/mt.2012.163 22910292 PMC3519989

122. Mi Z. Guo H. Russell M.B. Liu Y. Sullenger B.A. Kuo P.C. RNA aptamer blockade of osteopontin inhibits growth and metastasis of mda-mb231 breast cancer cells Mol. Ther. 2009 17 153 161 10.1038/mt.2008.235 18985031 PMC2834992

123. Talbot L.J. Mi Z. Bhattacharya S.D. Kim V. Guo H. Kuo P.C. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells Surgery 2011 150 224 230 10.1016/j.surg.2011.05.015 21801960 PMC3148491

124. Zhang X. Zhang J. Ma Y. Pei X. Liu Q. Lu B. Jin L. Wang J. Liu J. A cell-based single-stranded DNA aptamer specifically targets gastric cancer Int. J. Biochem. Cell Biol. 2014 46 1 8 10.1016/j.biocel.2013.10.006 24501772

125. Cao H.Y. Yuan A.H. Chen W. Shi X.S. Miao Y. A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer BMC Cancer 2014 14 699 10.1186/1471-2407-14-699 25248985 PMC4242496

126. Li S. Wang W. Ding H. Xu H. Zhao Q. Li J. Li H. Xia W. Su X. Chen Y. Aptamer BC15 against heterogeneous nuclear ribonucleoprotein A1 has potential value in diagnosis and therapy of hepatocarcinoma Nucleic Acid Ther. 2012 22 391 398 23062008 10.1089/nat.2012.0363

127. Dassie J.P. Hernandez L.I. Thomas G.S. Long M.E. Rockey W.M. Howell C.A. Chen Y. Hernandez F.J. Liu X.Y. Wilson M.E. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen Mol. Ther. 2014 22 1910 1922 10.1038/mt.2014.117 24954476 PMC4429728

128. Mann A.P. Somasunderam A. Nieves-Alicea R. Li X. Hu A. Sood A.K. Ferrari M. Gorenstein D.G. Tanaka T. Identification of thioaptamer ligand against E-selectin: Potential application for inflamed vasculature targeting PLoS ONE 2010 5 e13050 10.1371/journal.pone.0013050 20927342 PMC2948018

129. Kang S.A. Hasan N. Mann A.P. Zheng W. Zhao L. Morris L. Zhu W. Zhao Y.D. Suh K.S. Dooley W.C. Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis Mol. Ther. 2015 23 1044 1054 10.1038/mt.2015.45 25815697 PMC4817749

130. Kang S.A. Blache C.A. Bajana S. Hasan N. Kamal M. Morita Y. Gupta V. Tsolmon B. Suh K.S. Gorenstein D.G. The effect of soluble E-selectin on tumor progression and metastasis BMC Cancer 2016 16 331 27220365 10.1186/s12885-016-2366-2 PMC4879723

131. McNamara J.O. Kolonias D. Pastor F. Mittler R.S. Chen L. Giangrande P.H. Sullenger B. Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8 + T cells and inhibit tumor growth in mice J. Clin. Investig. 2008 118 376 386 10.1172/JCI33365 18060045 PMC2104483

132. Dollins C.M. Nair S. Boczkowski D. Lee J. Layzer J.M. Gilboa E. Sullenger B.A. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer Chem. Biol. 2008 15 675 682 10.1016/j.chembiol.2008.05.016 18635004 PMC2525512

133. Pratico E.D. Sullenger B.A. Nair S.K. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40 Nucleic Acid Ther. 2013 23 35 43 10.1089/nat.2012.0388 23113766 PMC3569954

134. Pastor F. Soldevilla M.M. Villanueva H. Kolonias D. Inoges S. de Cerio A.L. Kandzia R. Klimyuk V. Gleba Y. Gilboa E. CD28 aptamers as powerful immune response modulators Mol. Ther. Nucleic Acids 2013 2 e98 10.1038/mtna.2013.26 23756353 PMC3696906

135. Santulli-Marotto S. Nair S.K. Rusconi C. Sullenger B. Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity Cancer Res. 2003 63 7483 7489 14612549

136. Pastor F. Kolonias D. McNamara J.O. 2nd Gilboa E. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers Mol. Ther. 2011 19 1878 1886 10.1038/mt.2011.145 21829171 PMC3188744

137. Eder J.P. Vande Woude G.F. Boerner S.A. LoRusso P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin. Cancer Res. 2009 15 2207 2214 10.1158/1078-0432.CCR-08-1306 19318488

138. Schrand B. Berezhnoy A. Brenneman R. Williams A. Levay A. Kong L.Y. Rao G. Zhou S. Heimberger A.B. Gilboa E. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy Cancer Immunol. Res. 2014 2 867 877 10.1158/2326-6066.CIR-14-0007 24938283 PMC5502823

139. Prodeus A. Abdul-Wahid A. Fischer N.W. Huang E.H. Cydzik M. Gariepy J. Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers Mol. Ther. Nucleic Acids 2015 4 e237 10.1038/mtna.2015.11 25919090 PMC4417124

140. Lai W.Y. Huang B.T. Wang J.W. Lin P.Y. Yang P.C. A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects Mol. Ther. Nucleic Acids 2016 5 e397 10.1038/mtna.2016.102 27959341

141. Berezhnoy A. Stewart C.A. McNamara J.O. 2nd Thiel W. Giangrande P. Trinchieri G. Gilboa E. Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing Mol. Ther. 2012 20 1242 1250 10.1038/mt.2012.18 22434135 PMC3369303

142. Roth F. De La Fuente A.C. Vella J.L. Zoso A. Inverardi L. Serafini P. Aptamer-mediated blockade of IL4α triggers apoptosis of mdscs and limits tumor progression Cancer Res. 2012 72 1373 1383 10.1158/0008-5472.CAN-11-2772 22282665

143. Zheng J. Zhao S. Yu X. Huang S. Liu H.Y. Simultaneous targeting of CD44 and epcam with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth Theranostics 2017 7 1373 1388 10.7150/thno.17826 28435472 PMC5399600

144. Hervas-Stubbs S. Soldevilla M.M. Villanueva H. Mancheno U. Bendandi M. Pastor F. Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy Oncotarget 2016 7 4522 4530 10.18632/oncotarget.6608 26683225 PMC4826223

145. Soldevilla M.M. Villanueva H. Bendandi M. Inoges S. Lopez-Diaz de Cerio A. Pastor F. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia Biomaterials 2015 67 274 285 10.1016/j.biomaterials.2015.07.020 26231918

146. Huang B.T. Lai W.Y. Chang Y.C. Wang J.W. Yeh S.D. Lin E.P. Yang P.C. A CTLA-4 antagonizing DNA aptamer with antitumor effect Mol. Ther. Nucleic Acids 2017 8 520 528 10.1016/j.omtn.2017.08.006 28918052 PMC5573796

147. Ajona D. Ortiz-Espinosa S. Moreno H. Lozano T. Pajares M.J. Agorreta J. Bertolo C. Lasarte J.J. Vicent S. Hoehlig K. A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis Cancer Discov. 2017 7 694 703 10.1158/2159-8290.CD-16-1184 28288993

148. Drolet D.W. Green L.S. Gold L. Janjic N. Fit for the eye: Aptamers in ocular disorders Nucleic Acid Ther. 2016 26 127 146 10.1089/nat.2015.0573 26757406 PMC4900223

149. Eyetech Study G. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration Retina 2002 22 143 152 10.1097/00006982-200204000-00002 11927845

150. Zhang H. Berezov A. Wang Q. Zhang G. Drebin J. Murali R. Greene M.I. ErbB receptors: From oncogenes to targeted cancer therapies J. Clin. Investig. 2007 117 2051 2058 10.1172/JCI32278 17671639 PMC1934579

151. Yarden Y. Sliwkowski M.X. Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2001 2 127 137 10.1038/35052073 11252954

152. Gala K. Chandarlapaty S. Molecular pathways: HER3 targeted therapy Clin. Cancer Res. 2014 20 1410 1416 10.1158/1078-0432.CCR-13-1549 24520092 PMC3977203

153. Chen C.H. Chernis G.A. Hoang V.Q. Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 Proc. Natl. Acad. Sci. USA 2003 100 9226 9231 10.1073/pnas.1332660100 12874383 PMC170900

154. Berger C.M. Gaume X. Bouvet P. The roles of nucleolin subcellular localization in cancer Biochimie 2015 113 78 85 10.1016/j.biochi.2015.03.023 25866190

155. Rosenberg J.E. Bambury R.M. Van Allen E.M. Drabkin H.A. Lara P.N. Harzstark A.L. Wagle N. Figlin R.A. Smith G.W. Garraway L.A. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Investig. New Drugs 2014 32 178 187 10.1007/s10637-013-0045-6 24242861 PMC4560460

156. Koutsioumpa M. Papadimitriou E. Cell surface nucleolin as a target for anti-cancer therapies Recent Pat. Anticancer Drug Discov. 2014 9 137 152 10.2174/1574892808666131119095953 24251811

157. Girvan A.C. Teng Y. Casson L.K. Thomas S.D. Jüliger S. Ball M.W. Klein J.B. Pierce W.M. Barve S.S. Bates P.J. AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin Mol. Cancer Ther. 2006 5 1790 1799 10.1158/1535-7163.MCT-05-0361 16891465

158. Soundararajan S. Chen W. Spicer E.K. Courtenay-Luck N. Fernandes D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl -2 messenger RNA in human breast cancer cells Cancer Res. 2008 68 2358 2365 10.1158/0008-5472.CAN-07-5723 18381443

159. Jain N. Zhu H. Khashab T. Ye Q. George B. Mathur R. Singh R.K. Berkova Z. Wise J.F. Braun F.K. Targeting nucleolin for better survival in diffuse large B-cell lymphoma Leukemia 2017 32 663 674 10.1038/leu.2017.215 28690315 PMC5829046

160. Gros A. Robbins P.F. Yao X. Li Y.F. Turcotte S. Tran E. Wunderlich J.R. Mixon A. Farid S. Dudley M.E. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors J. Clin. Investig. 2014 124 2246 2259 10.1172/JCI73639 24667641 PMC4001555

161. Sayyed S.G. Hägele H. Kulkarni O.P. Endlich K. Segerer S. Eulberg D. Klussmann S. Anders H.-J. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes Diabetologia 2009 52 2445 2454 10.1007/s00125-009-1493-6 19707743

162. Marasca R. Maffei R. NOX-A12: Mobilizing CLL away from home Blood 2014 123 952 953 10.1182/blood-2013-12-542480 24526776

163. Guo F. Wang Y. Liu J. Mok S.C. Xue F. Zhang W. CXCL12/CXCR4: A symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks Oncogene 2016 35 816 826 10.1038/onc.2015.139 25961926

164. Feig C. Jones J.O. Kraman M. Wells R.J. Deonarine A. Chan D.S. Connell C.M. Roberts E.W. Zhao Q. Caballero O.L. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer Proc. Natl. Acad. Sci. USA 2013 110 20212 20217 10.1073/pnas.1320318110 24277834 PMC3864274

165. Mann A.P. Bhavane R.C. Somasunderam A. Liz Montalvo-Ortiz B. Ghaghada K.B. Volk D. Nieves-Alicea R. Suh K.S. Ferrari M. Annapragada A. Thioaptamer conjugated liposomes for tumor vasculature targeting Oncotarget 2011 2 298 304 10.18632/oncotarget.261 21666286 PMC3248173

166. Mann A.P. Tanaka T. Somasunderam A. Liu X. Gorenstein D.G. Ferrari M. E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow Adv. Mater. 2011 23 H278 H282 10.1002/adma.201101541 21833996

167. Mai J. Huang Y. Mu C. Zhang G. Xu R. Guo X. Xia X. Volk D.E. Lokesh G.L. Thiviyanathan V. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer J. Control. Release 2014 187 22 29 10.1016/j.jconrel.2014.04.057 24818768 PMC4109393

168. Nishino M. Ramaiya N.H. Hatabu H. Hodi F.S. Monitoring immune-checkpoint blockade: Response evaluation and biomarker development Nat. Rev. Clin. Oncol. 2017 14 655 668 10.1038/nrclinonc.2017.88 28653677 PMC5650537

169. Mangala L.S. Wang H. Jiang D. Wu S.Y. Somasunderam A. Volk D.E. Lokesh G.L. Li X. Pradeep S. Yang X. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy JCI Insight 2016 1 e87754 10.1172/jci.insight.87754 27777972 PMC5070952

170. Melero I. Hervas-Stubbs S. Glennie M. Pardoll D.M. Chen L. Immunostimulatory monoclonal antibodies for cancer therapy Nat. Rev. Cancer 2007 7 95 106 10.1038/nrc2051 17251916

171. Attarwala H. TGN1412: From discovery to disaster J. Young Pharm. 2010 2 332 336 10.4103/0975-1483.66810 21042496 PMC2964774

172. Bartkowiak T. Curran M.A. 4-1BB agonists: Multi-potent potentiators of tumor immunity Front. Oncol. 2015 5 117 10.3389/fonc.2015.00117 26106583 PMC4459101

173. Schrand B. Berezhnoy A. Brenneman R. Williams A. Levay A. Gilboa E. Reducing toxicity of 4-1BB costimulation: Targeting 4-1BB ligands to the tumor stroma with BI-specific aptamer conjugates Oncoimmunology 2015 4 e970918 10.4161/21624011.2014.970918 25949891 PMC4404909

174. Soldevilla M.M. Villanueva H. Casares N. Lasarte J.J. Bendandi M. Inoges S. Lopez-Diaz de Cerio A. Pastor F. MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells Oncotarget 2016 7 23182 23196 10.18632/oncotarget.8095 26992239 PMC5029619

175. Rusconi C.P. Scardino E. Layzer J. Pitoc G.A. Ortel T.L. Monroe D. Sullenger B.A. RNA aptamers as reversible antagonists of coagulation factor IXa Nature 2002 419 90 94 10.1038/nature00963 12214238

176. Bompiani K.M. Monroe D.M. Church F.C. Sullenger B.A. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity J. Thromb. Haemost. 2012 10 870 880 10.1111/j.1538-7836.2012.04679.x 22385910 PMC3636572

177. Ng E.W.M. Shima D.T. Calias P. Cunningham E.T. Jr. Guyer D.R. Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat. Rev. Drug Dis. 2006 5 123 132 10.1038/nrd1955 16518379

178. Jellinek D. Green L.S. Bell C. Janjic N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor Biochemistry 1994 33 10450 10456 10.1021/bi00200a028 7520755

179. Green L.S. Jellinek D. Bell C. Beebe L.A. Feistner B.D. Gill S.C. Jucker F.M. Janjić N. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor Chem. Biol. 1995 2 683 695 10.1016/1074-5521(95)90032-2 9383475

180. Study of AS1411 in Advanced Solid Tumours Available online: https://ClinicalTrials.gov/show/NCT00881244 (accessed on 12 December 2017)

181. A phase II Study of AS1411 in Renal Cell Carcinoma Available online: https://ClinicalTrials.gov/show/NCT00740441 (accessed on 12 December 2017)

182. Phase II Study of AS1411 Combined with Cytarabine to Treat Acute Myeloid Leukemia Available online: https: //ClinicalTrials.gov/show/NCT00512083 (accessed on 12 December 2017)

183. Soundararajan S. Wang L. Sridharan V. Chen W. Courtenay-Luck N. Jones D. Spicer E.K. Fernandes D.J. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells Mol. Pharmacol. 2009 76 984 991 10.1124/mol.109.055947 19657047 PMC2774992

184. Chen W. Sridharan V. Soundararajan S. Otake Y. Stuart R. Jones D. Fernandes D. Activity and mechanism of action of AS1411 in acute myeloid leukemia cells Blood 2007 110 1604

185. Stuart R.K. Stockerl-Goldstein K. Cooper M. Devetten M. Herzig R. Medeiros B. Schiller G. Wei A. Acton G. Rizzieri D. Randomized phase ii trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML) J. Clin. Oncol. 2009 27 7019

186. Olaptesed (NOX-A12) Alone and in Combination with Pembrolizumab in Colorectal and Pancreatic Cancer Available online: https://ClinicalTrials.gov/show/NCT03168139 (accessed on 12 December 2017)

187. NOX-A12 First-in-Human (FIH) Study Available online: https://ClinicalTrials.gov/show/NCT00976378 (accessed on 12 December 2017)

188. NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers Available online: https://ClinicalTrials.gov/show/NCT01194934 (accessed on 12 December 2017)

189. Waldschmidt J.M. Simon A. Wider D. Muller S.J. Follo M. Ihorst G. Decker S. Lorenz J. Chatterjee M. Azab A.K. Cxcl12 and Cxcr7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma Br. J. Haematol. 2017 179 36 49 10.1111/bjh.14807 28670693

190. Roccaro A.M. Sacco A. Purschke W.G. Moschetta M. Buchner K. Maasch C. Zboralski D. Zollner S. Vonhoff S. Mishima Y. SDF-1 inhibition targets the bone marrow niche for cancer therapy Cell Rep. 2014 9 118 128 10.1016/j.celrep.2014.08.042 25263552 PMC4194173

191. NOX-A12 in Combination with Bortezomib and Dexamethasone in Relapsed Multiple Myeloma Available online: https://ClinicalTrials.gov/show/NCT01521533 (accessed on 12 December 2017)

192. Ludwig H. Weisel K. Petrucci M.T. Leleu X. Cafro A.M. Garderet L. Leitgeb C. Foa R. Greil R. Yakoub-Agha I. Olaptesed pegol, an anti-CXCL12/SDF-1 spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: A phase IIa study Leukemia 2017 31 997 1000 10.1038/leu.2017.5 28074071 PMC5383929

193. NOX-A12 in Combination with Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) Available online: https://ClinicalTrials.gov/show/NCT01486797 (accessed on 12 December 2017)

194. Steurer M. Montillo M. Scarfò L. Mauro F.R. Andel J. Wildner S. Trentin L. Janssens A. Burgstaller S. Kruschinski A. Results from a phase IIa study of the anti-CXCL12 spiegelmer olaptesed pegol (NOX-A12) in combination with bendamustine/rituximab in patients with chronic lymphocytic leukemia Blood 2014 124 1996

195. Buffery D. The 2015 oncology drug pipeline: Innovation drives the race to cure cancer Am. Health Drug Benefits 2015 8 216 222 26157543 PMC4489190